Neurocrine Biosciences Inc.

11/12/2024 | Press release | Distributed by Public on 11/12/2024 16:59

Statement of Changes in Beneficial Ownership - Form 4

Ownership Submission
FORM 4
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287 Estimated average burden hours per response... 0.5
(Print or Type Responses)
1. Name and Address of Reporting Person *
ROBERTS EIRY
2. Issuer Name and Ticker or Trading Symbol
NEUROCRINE BIOSCIENCES INC [NBIX] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner
__X__ Officer (give title below) _____ Other (specify below)
Chief Medical Officer
(Last) (First) (Middle)
12780 EL CAMINO REAL 		3. Date of Earliest Transaction (Month/Day/Year)
11/08/2024
(Street)
SAN DIEGO, CA 92130 		4. If Amendment, Date Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City) (State) (Zip)
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I)
(Instr. 4) 		7. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 11/08/2024 M(1) 5,140 A $77.81 28,856 D
Common Stock 11/08/2024 M(1) 1,233 A $81.05 30,089 D
Common Stock 11/08/2024 M(1) 971 A $102.9 31,060 D
Common Stock 11/08/2024 M(1) 1 A $79.02 31,061(2) D
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. SEC 1474 (9-02)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 3) 		2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code
(Instr. 8) 		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4, and 5) 		6. Date Exercisable and Expiration Date
(Month/Day/Year) 		7. Title and Amount of Underlying Securities
(Instr. 3 and 4) 		8. Price of Derivative Security
(Instr. 5) 		9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 4) 		10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 4) 		11. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Incentive Stock Option $77.81 11/08/2024 M 5,140 (3) 01/08/2028 Common Stock 5,140 $ 0 0 D
Incentive Stock Option $81.05 11/08/2024 M 1,233 (4) 02/07/2029 Common Stock 1,233 $ 0 0 D
Incentive Stock Option $102.9 11/08/2024 M 971 (5) 02/06/2030 Common Stock 971 $ 0 0 D
Incentive Stock Option $79.02 11/08/2024 M 1 (6) 01/31/2032 Common Stock 1 $ 0 1,265 D

Reporting Owners

Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
ROBERTS EIRY
12780 EL CAMINO REAL
SAN DIEGO, CA 92130 		Chief Medical Officer

Signatures

/s/ Darin Lippoldt, Attorney-in-Fact 11/12/2024
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) This transaction involved a cash exercise of a stock option without a subsequent sale of the underlying shares of common stock.
(2) 29,876 of the outstanding shares are held by The Stephen Tayor and Eiry W. Roberts Joint Trust Agreement, of which Dr. Roberts has voting and investment power.
(3) Represents option of which 1/4th of the shares underlying the option became vested and exercisable on January 8, 2019 and an additional 1/48th of the shares underlying the option became vested and excercisable each month thereafter.
(4) Represents option of which 1/48th of the shares underlying the option became vested and exercisable on March 7, 2019 and an additional 1/48th of the shares underlying the option became vested and excercisable each month thereafter.
(5) Represents option of which 1/48th of the shares underlying the option became vested and exercisable on March 6, 2020 and an additional 1/48th of the shares underlying the option became vested and excercisable each month thereafter.
(6) Represents option of which 1/48th of the shares underlying the option became vested and exercisable on February 28, 2022 and an additional 1/48th of the shares underlying the option becomes vested and excercisable each month thereafter.
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.